Michael G. Shlipak, MD, MPH
Chief, Division of General Internal Medicine, SFVAMC
Professor In-Residence, Departments of Medicine, Epidemiology & Biostatistics, UCSF
Dr. Shlipak is Chief of General Internal Medicine at the San Francisco VA Medical Center and a Professor of Medicine at the University of California, San Francisco School of Medicine. He graduated from Harvard Medical School and obtained his MPH from the Harvard School of Public Health. He completed internal medicine residency and a General Internal Medicine fellowship at UCSF. His research activities involve the detection and the determinants of kidney disease, and its association with adverse outcomes, including cardiovascular disease. He has been particularly focused on the use of cystatin C as a novel indicator of kidney function and its potential to improve understanding of kidney disease epidemiology and clinical care. He coined the entity of preclinical kidney disease to describe the large population of elders with elevated cystatin C levels, but normal creatinine-based estimates of kidney function, who are at high risk for death and cardiovascular disease.
Recent work for his research group has been dedicated to finding early markers of kidney injury in the urine that will precede any detectable loss in kidney function. They study these urine biomarkers in several populations, including the ambulatory elderly, HIV-infected men and women, and in population-based studies. They believe that these injury markers hold promise both for understanding how various exposures impact the kidney, and also to forecast future declines in kidney failure.
Dr. Shlipak’s research has been continuously funded by NIH grants for the past 15 years, in addition to research grants from the Robert Wood Johnson Foundation, the American Heart Association and the American Federation for Aging Research.
He is the author of over 300 peer-reviewed manuscripts and recently was 1 of 16 co-authors for the 2013 KDIGO Guidelines on Definition and Classification of Chronic Kidney Disease.
To see Dr. Shlipak on Pub Med, click here.